CrystalGenomics' Covid treatment performs well in trials
CrystalGenomics said Thursday that animal tests of its oral Covid-19 treatment candidate confirmed its effectiveness against the Delta variant.
The company conducted tests on mice infected with the Delta variant and found that those that were administrated with the drug showed 63 times lower viral loads than the control group.
CrystalGenomics is preparing to start Phase 2 clinical trials of the candidate in the United States, with the aim of developing a drug to treat lung inflammation and fibrosis caused by the coronavirus.
“Based on the results that proved the candidate’s effectiveness against the Delta variant, we will speed up the development of the oral treatment,” said a spokesperson for CrystalGenomics in Thursday’s statement.
BY SARAH CHEA [email@example.com]
with the Korea JoongAng Daily
To write comments, please log in to one of the accounts.
Standards Board Policy (0/250자)